Skip to main content
Rumey C. Ishizawar, MD, PhD – Division of Rheumatology, Allergy, and Immunology

Rumey C. Ishizawar, MD, PhD

Assistant Professor of Medicine

Director, UNC Rheumatology Fellowship Program

Rumey Ishizawar, MD

Contact Information

Address

Office:
3300 Thurston Building
CB#7280
Chapel Hill, NC 27599

Resources

Rumey C. Ishizawar, MD, PhD

Assistant Professor of Medicine

Director, UNC Rheumatology Fellowship Program

Areas of Interest

General rheumatology, evaluating and managing inflammatory arthritis, immuno-oncology, medical education.

About

Publications

Books and Chapters

  1. Medlin J, Ishizawar R. Chapter 8: Felty’s Syndrome. (pg 157-171) In: Rare Rheumatic Diseases of Immunological Dysregulation. Ed: Teresa K. Tarrant. 2019. Springer International Publishing Ed. 1.
  2. Ishizawar, R. Miscellaneous Rheumatic Diseases. In: Brigham and Women’s Experts’ Approach to Rheumatology, Coblyn JS, Bermas B, Weinblatt M, and Helfgott S editors. Jones and Bartlett Learning, LLC, 2011, pp. 175-196.

Primary Research

    1. Simarro M, Giannattasio G, De la Fuente MA, Benarafa C, Subramanian KK, Ishizawar R, Balestrieri B, Andersson EM, Luo HR, Orduña A, Boyce J, Anderson P. Fas-activated serine/threonine phosphoprotein promotes immune-mediated pulmonary inflammation. J Immunol, 2010;184(9):5325-32.
    2. Ishizawar RC, Miyake T, Parsons SJ. c-Src modulates ErbB2 and ErbB3 heterocomplex formation and function. Oncogene, 2007;26(24):3503-10. 3. Ishizawar RC, Tice DA, Karaoli T, Parsons SJ. The C terminus of c-Src inhibits breast tumor cell growth by a kinase-independent mechanism. J Biol Chem, 2004;279(22):23773-81.

Atchley WT, Alvarez C, Saxena-Beem S, Schwartz TA, Ishizawar RC, Patel KP, Rivera MP. Immune Checkpoint Inhibitor-Related Pneumonitis in Lung Cancer: Real-World Incidence, Risk Factors, and Management Practices Across Six Health Care Centers in North Carolina. Chest. 2021 Aug;160(2):731-742. doi: 10.1016/j.chest.2021.02.032. Epub 2021 Feb 20. PMID: 33621599

Clinical Reports

  1. Henderson LA, Loring SH, Gill RR, Liao KP, Ishizawar R, Kim S, Perlmutter-Goldenson R, Rothman D, Son MB, Stoll ML, Zemel LS, Sandborg C, Dellaripa PF, Nigrovic PA. Shrinking lung syndrome as a manifestation of pleuritis: a new model based on pulmonary physiological studies. J Rheumatol, 2013;40(3):273-81.
  2. Velez NF, Ishizawar RC, Dellaripa PF, Saavedra AP, Laga AC, Murphy GF, Fisher DC, Kupper TS, Vleugels RA. Full facial edema: a novel presentation of subcutaneous panniculitis-like T-cell lymphoma. J Clin Oncol, 2012;30(25):e233-6.

Invited Reviews

  1. Ishizawar R, Parsons SJ. c-Src and cooperating partners in human cancer. Cancer Cell 2004; 6(3):209-14.
  2. Biscardi JS, Ishizawar RC, Silva CM, Parsons SJ. Tyrosine kinase signaling in breast cancer: epidermal growth factor receptor and c-Src interactions in breast cancer. Breast Cancer Res. 2000;2(3):203-10.

Abstracts

  1. Cunningham M, Alvarez C, Saxena Beem S, Schwartz T, Ishizawar R. Neutrophil to Lymphocyte Ratio as a Predictor of Immune-Related Adverse Events in CTLA-4 Treated Patients: A Retrospective Review. ACR Convergence 2020. Abstract ID: 909225
  2. Atchley W, Alvarez C, Saxena Beem S, Schwartz TA, Ishizawar RC, Patel KP, Rivera M. Immune Checkpoint Inhibitor-Related Pneumonitis in Lung Cancer: A Retrospective Multi-Site Assessment of Real-World Incidence, RiskFactors, and Management Practices. American Thoracic Society Annual Meeting 2020 (canceled due to COVID-19). Online. Am J Respir Crit Care Med 2020;201:A6179. Internet address: www.atsjournals.org
  3. Romero R, Schwartz T, Saxena Beem S, and Ishizawar RC. Immune Related Adverse Events from Immune Checkpoint Inhibitors: A Retrospective Analysis from 2004-2017 at the University of North Carolina at Chapel Hill. 2018 American College of Rheumatology Annual Meeting. October 19-24, 2018. Chicago, IL – Abstract #356
  4. Ishizawar RC, Lester CL, Cui J, Doench J, Plenge RM* and Brenner MB*. A Functional Genomic Screen of Rheumatoid Arthritis Risk Genes in Primary Human T Cells Reveals DDX6 As a Negative Modulator of Cytokine Expression. 2016 American College of Rheumatology Annual Meeting. November 11-16, 2016. Washington D.C. – Abstract #1567
  5. Ishizawar RC, Lester CL, Duclos G, Brenner MB, and Plenge RM. Rheumatoid Arthritis Risk Genes in CD4+ T cell Biology. ACR Rheumatology Research Workshop. June 21-23, 2013. Dallas Fairmont Hotel, Dallas, Texas – Abstract #FAC007
  6. Ishizawar RC and Parsons SJ. HER2, HER3, and c-Src cooperative interactions in breast cancer. Era of Hope Department of Defense Breast Cancer Research Meeting. Sept 25-28, 2002. Orange county Convention Center, Orlando, Florida- Poster Session P1-12.
  7. Ishizawar RC and Parsons SJ. Interactions between HER2, HER3, and c-Src in two breast cancer model systems. 93rd American Association of Cancer Research Annual Meeting. April 6-10, 2002. Moscone Convention Center, San Francisco, CA. Cell and Tumor Biology 32: Receptor Signaling I: EGFR/ERBR/Breast Cancer Poster Session-Abstract #3561.
  8. Ishizawar RC and Parsons SJ. Interactions between HER2, HER3, and c-Src in two breast cancer model systems. 10th Annual Graduate Biosciences Society Spring Student Research Symposium and Poster Session. April 23, 2002. Jordan Hall, University of Virginia, Charlottesville, VA. Poster #29.
  9. Ishizawar RC, Tice DA, Lavelle D, Karaoli T, and Parsons SJ. c-Src as a potential therapeutic target for human mammary carcinoma. Keystone Symposia: Advances in Human Breast and Prostate Cancer. March 19-24, 2000. Incline Village, NV. Poster session 3-#305 and Presentation in Workshop 1: Breast Cancer

  • Undergraduate

    Brown University

  • Medical School

    School of Medicine, University of Virginia

  • Residency

    Brigham and Women’s Hospital

  • Fellowship

    Brigham and Women’s Hospital

  • PhD

    Graduate School of Arts and Sciences, University of Virginia